

Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	04843/113003
	Serial No.	10/646,063
	Applicant	Martin H. Teicher et al.
	Filing Date	August 22, 2003
	Group	1654
	IDS Filed	September 30, 2005
Customer No.	21559	

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
mmc6	4,427,649	01/24/1984	Dingle et al.			
	4,443,440	04/17/1984	Anderson et al.			
	4,456,602	06/26/1984	Anderson et al.			
	4,609,496	09/02/1986	Eisenbrand et al.			
	4,469,689	09/04/1984	Anderson et al.			
	4,472,392	09/18/1984	Anderson et al.			
	4,678,609	07/07/1987	Engels, Joachim			
	4,948,533	08/14/1990	Braughler et al.			
	5,338,837	08/16/1994	Kahne, Daniel E.			
	5,571,795	11/05/1996	Kahne et al.			
	5,599,807	02/04/1997	Ogata et al.			
	5,614,514	03/25/1997	Axelsson et al.			
	5,627,270	05/06/1997	Kahne et al.			
	5,674,861	10/07/1997	Anderson et al.			
	5,693,769	12/02/1997	Kahne et al.			
	5,762,918	06/09/1998	Thorpe, Philip E.			
mmc6	5,888,995	03/30/1999	Axelsson et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
EXAMINER <i>Mark M Cordova</i>			DATE CONSIDERED <i>11/25/05</i>			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

Sheet 2 of 2

<b>SUBSTITUTE FORM PTO-1449</b> (MODIFIED)  <b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	<b>Attorney Docket No.</b>	04843/113003
	<b>Serial No.</b>	10/646,063
	<b>Applicant</b>	Martin H. Teicher et al.
	<b>Filing Date</b>	August 22, 2003
	<b>Group</b>	1654
	<b>IDS Filed</b>	September 30, 2005
	<b>Customer No.</b>	21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
mmC6	Welinder, K., "Amino acid sequence studies of horseradish peroxidase. Tryptic glycopeptide containing two histidine residues and a disulfide bridge," <i>FEBS Letters</i> 30(2):243 (1973).
	Krupin et al., "Topical corticosteroid therapy and pituitary-adrenal function," <i>Arch. Ophthalmol.</i> 94(6):919 (1976).
	Miyabo et al., "A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in man," <i>Eur. J. Clin. Pharmacol.</i> 20(4):277 (1981).
	Petersen et al., "Pharmacokinetics of betamethasone in healthy adults after intravenous administration," <i>Eur. J. Clin. Pharmacol.</i> 25(5):643 (1983).
	Eryomin et al., "Interaction of steroid-peroxidase conjugates with cellulose immunosorbants in aqueous and micellar media," <i>Biochemistry (Moscow)</i> 63(10):1148 (1998).
	Brown et al., "Hippocampal remodeling and damage by corticosteroids: implications for mood disorders," <i>Neuropsychopharmacology</i> 21(4):474 (1999).
	Killian et al., "Modulating blood-brain barrier interactions of amino acid-based anticancer agents," <i>Drug Delivery</i> 7(1):21 (2000).
	Haynes et al., "Dexamethasone induces limited apoptosis and extensive sublethal damage to specific subregions of the striatum and hippocampus: implications for mood disorders," <i>Neuroscience</i> 104(1):57 (2001).
mmC6	Rossi et al., "Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease," <i>Biotechnol. Appl. Biochem.</i> 33(Pt 2):85 (2001).

<b>EXAMINER</b> <i>Martha M. Cordova Jr.</i>	<b>DATE CONSIDERED</b> <i>11/25/05</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	